Early restenosis after drug-eluting stent implantation: A putative role for platelet activation

Canadian Journal of Cardiology

Volumn 23, Issue 1, 2007, Pages 57-59

  Tamburino, Corrado ^a   Ussia, Gian Paolo ^a   Zimarino, Marco ^b   Gallasi, Alfredo R ^a   De Caterina, Raffaele ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

'Thrombus; Angioplasty; Restenosis; Stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTERY GRAFT; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BALLOON DILATATION; CASE REPORT; CORONARY ARTERY BYPASS SURGERY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GRAFT OCCLUSION; GRAFT PATENCY; HUMAN; IN-STENT RESTENOSIS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PERCUTANEOUS CORONARY INTERVENTION; THROMBOCYTE ACTIVATION; TREATMENT DURATION; BLOOD VESSEL TRANSPLANTATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MONITORING; PATHOLOGY; PATHOPHYSIOLOGY; RESTENOSIS; RISK ASSESSMENT; RISK FACTOR; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR ENDOTHELIUM;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; DRUG MONITORING; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; PLATELET ACTIVATION; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS;

EID: 33847733515     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70214-3     Document Type: Letter

References (12)

1. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-70.
2. Moses JW, Leon MB, Popma JJ, et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
3. Stone GW, Ellis SG, Cox DA, et al; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
4. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
5. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000;86:6H-11H.
6. Bar-Shavit R, Benezra M, Eldor A, et al. Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: Nonenzymatic mode of action. Cell Regul 1990;1:453-63. (Erratum in 1990;1:873).
7. Banai S, Wolf Y, Golomb G, et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 1998;97:1960-9.
8. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated scents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998;352:673-81. (Erratum in 1998;352:1478).
9. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999;100:21-6.
10. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
11. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 2005;111:1619-26.
12. Zimarino M, Renda G, De Caterina R. Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents. Drugs 2005;65:725-32.